On September 3, 2010, the Centers for Medicare & Medicaid Services (“CMS”) issued a proposed rule withdrawing regulations governing the determination of “Average Manufacturer Price” (“AMP”), the definition of “Multiple Source Drug,” and the application of federal upper reimbursement limits (“FULs”) for Multiple Source Drugs (the “Proposed Rule”). This withdrawal would impact the applicable regulations finalized by CMS in 2007 and 2008 but would leave intact other sections of the 2007 regulations, including, for example, the “Best Price” provisions and certain “definitions” (including the definition of “bona fide service fee”). Comments may be submitted to CMS until 5:00 p.m. EDT on October 4, 2010. We recommend that organizations consider commenting on the impact of the withdrawn regulations, as well as on the open items that have not been addressed under the recent “health reform” legislation.
The Proposed Rule is in response to the changes made to the Medicaid Drug Rebate Program statute by recent health reform legislation. As discussed in greater detail in our March 31, 2010, client alert titled Medicaid Drug Rebate Program ‘Reform’: Key Considerations and Implementation Tips for Pharmaceutical and Biotech Manufacturers (/publications/health-reform-medicaid-drug-rebate-program-reform-key-considerations-and-implementation-tips-for-pharmaceutical-and-biotech-manufacturers/), Section 2503 of the Patient Protection and Affordable Care Act (“PPACA”) significantly revised the calculation of AMP, the determination of FULs, and the definition of “Multiple Source Drug.” Such changes are to take effect October 1, 2010. The definition of AMP was further revised by the Education Jobs and Medicaid Assistance Act, also effective October 1, 2010. The Proposed Rule would replace the current regulatory provisions with the revised statutory provisions set forth in PPACA, as amended (see box for new AMP definition).
The intent of the Proposed Rule is to ensure that the CMS regulations do not conflict with the amended Medicaid Drug Rebate Program statute. However, CMS’ proposed withdrawal, particularly the provision regarding determination of AMP, leaves several open issues. For example, in the Proposed Rule, CMS did not withdraw the definition of “bona fide service fees” set forth in the 2007 regulation, which included:
However, PPACA specifies that AMP excludes
If the current CMS regulations continue to modify the amended Medicaid Drug Rebate Statute’s use of “bona fide service fees,” then in some cases the statutorily itemized “bona fide service fees” might not qualify for exclusion under the regulatory definition. It is unclear whether this outcome is consistent with Congressional intent as there is no formal legislative history to PPACA. To the extent that a manufacturer previously had concluded that a category of fees itemized in PPACA could not be “bona fide service fees,” such manufacturer may want to reconsider its position. Additionally, the withdrawn AMP provision in the Proposed Rule would eliminate the regulatory definition of “customary prompt pay discount,” thus leaving an ambiguity as to the determination as to whether a discount is “customary.”
Although helpful in ensuring consistency, the Proposed Rule does not address some of the more difficult interpretation issues in the revised statutory AMP definition that will be effective October 1, 2010. For example, there remains uncertainty regarding the calculation methodology of AMP for products that are not “generally” dispensed through retail community pharmacies, including what the term “generally” means. There also is a lack of clarity regarding the data manufacturers will need in order to determine whether wholesaler sales are “distributed to retail community pharmacies.” Additionally, the Proposed Rule does not address whether manufacturers will be permitted to restate baseline AMPs in connection with the revised definitions. In this regard, PPACA requires that Section 2503 take effect on October 1, 2010, with or without CMS regulations. However, CMS states in the Proposed Rule that CMS intends to promulgate additional regulations regarding Section 2503, although no proposed time frame is provided.
Entities involved in the sale, promotion, purchase, or distribution of Medicaid covered drugs should review the Proposed Rule and consider taking advantage of the opportunity to seek CMS clarification on outstanding issues that may impact their respective businesses. The comment period ends at 5:00 p.m. EDT on October 4, 2010.
For more information about this issue of IMPLEMENTING HEALTH AND INSURANCE REFORM, please contact the author below or the member of the firm who normally handles your legal matters.
 75 Fed. Reg. 54,073 (Sept. 3, 2010).
 See42 C.F.R. §§ 447.500-447.520; see alsopreamble at 72 Fed. Reg. 39,142 (July 17, 2007) (pertaining to Medicaid Drug Rebate program generally); 73 Fed. Reg. 58,491 (Oct. 7, 2008) (pertaining to revised “Multiple Source Drug” definition).
 42 U.S.C. § 1392r-8 (Section 1927 of the Social Security Act).
 Pub. L. 111—148 (2010).
 Pub. L. 111—226 (2010).
 42 C.F.R. § 447.502.
Proposed CMS Rule
Medicaid Drug Rebate Program ‘Reform’:
OCTOBER 1, 2010
*Note that the impact on FULs will not be on October 1, 2010, despite the fact that the statute requires it. This is because the implementation of the FUL provisions will require the calculation of AMP under the new formula,and CMS will not have this data until November 30, 2010, at the earliest.